3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Carcinoma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Cancer Patients
1
Interventions
pembrolizumab
9
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Surgical Procedures, Operative
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
DEAE-Dextran
×
1 year
×
Clear all
NCT07403877
2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2
Not yet recruiting
114 enrolled